Glycan characterization is important in the process of protein drug development, from early stage candidate selection to late stage regulatory Submission.

Glycan variants of a glycoprotein product must be adequately analyzed and controlled to ensure product quality. The inherent complexity of protein glycosylation poses an analytical challenge.


Specific applications for Glycan Analysis


A Study on a Method for Evaluating Glycans in Biopharmaceuticals

Many protein-based biopharmaceutical products, typified by antibody drugs, are synthesized in cultured cells derived from eukaryotes such as CHO (Chinese hamster ovary) cells. For this reason, there are inevitably many post-translational modifications to the biosynthesized proteins. Among these, modifications of glycans have gained attention as items for evaluating the quality of biopharmaceuticals since they are associated with the adjustment of protein functions, as well as with the unwanted development of antigenicity depending on their structure. However, there are various technical challenges in evaluating glycans.

Suppressing Peeling Reactions in Pretreatment for O-glycan Analysis


Comparison of various pretreatment methods for N-Glycan Analysis



Analysis of Glycopeptides Using MALDImini 1 Compact MALDI Digital Ion Trap Mass Spectrometer

Glycans, which are one post-translational modification of proteins, are molecules with high structural heterogeneity which are formed by complex bonding of glucose, mannose, and other monosaccharides. It is known that their complex structure is related to regulation of protein functions, and various phenomenon can be observed depending on illness and other factors. These include abnormal glycan structures with the protein backbone and the absence of glycan bonding at sites where it is assumed that such bonding should occur. The information concerning complex glycan structures and the binding sites of glycan with the proteins is not coded directly in genes but is created by the action of a large number of glycosyltransferases, which act in the protein biosynthesis process.


Analysis of N-Linked Glycan using MALDImini 1 Compact MALDI Digital Ion Trap Mass Spectrometer - Structural Analysis and Identification of Sialyl Linkage Isomers

N-linked glycosylation to proteins plays an important role in various biological phenomena. In particular, sialic acids existing at sugar chain terminals and their linkage types are known to be key factors related to numerous diseases, such as antigenicity and viral infections. In recent years, mass spectroscopy (MS) has been widely used in glycan analysis. However, there were various problems related to sialic acid residues, in that they are unstable and thus easily lost while analysing, and furthermore, it is not possible to differentiate linkage isomers by MS. On the other hand, HPLC analysis is mainly used to identify the linkage type of sialic acids, but this method also has technical problems, for example, identification is difficult in the case of glycans with numerous sialic acids.


High Sensitivity Profiling of Glycans in Antibody Drugs Using RF-20AXS

Glycans, or sugar chains, in antibody drugs play roles in the antigenicity, pharmacokinetics, and stability of higher-order structure, which could adversely affect their safety and effectiveness. Further, there is also concern about the non-uniformity of these glycans due to instability of antibody drug culture conditions, which has heightened the necessity to manage their production process. However, while there is currently no glycan test method specified in the Japanese Pharmacopoeia, there is wide demand for an assessment method. Here, we introduce an example of analysis of glycans in antibody drugs using the Nexera X2 ultra high performance liquid chromatograph with the RF-20AXS high-sensitivity fluorescence detector. For the analysis, the Phenomenex core-shell, high-speed analytical AerisTM PEPTIDE XB-C18 column was used. Since the permeability of the packing material is optimized for analysis of high-molecular compounds such as peptides, the column is useful for separation of glycans and impurities in antibody drugs.


N-glycan Profiling of monoclonal Antibodies (mAb) on Nexera Bio UHPLC Coupled with Fluorescense Detector and Q-TOF Mass Spectrometer

N-linked Glcosylation on Asn residue with consensus sequence Asn-X-Ser/thr (where X is an amino acid except Pro) plays a critical role in stability, bioactivity and immunogenicity of monoclonal antibodies. The N-Glycan moieties of therapeutic mAbs, especially biosimilar products, must be adequately and routinely characterized to ensure product quality. In the report, we established a robust, sensitive and reproducible analytical platform that contains a Nexera Bio UHPLC system, a fluorescense detector and a Q-TOF mass spectrometer for N-Glycan profiling of bevacizumab biosimilar.


You would like to get more information about total solutions for glycan analysis?

Contact our Biopharma Specialist 

Top of This Page